Topical Nepafenac as Supplement for Diabetic Macular Edema
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Diabetic macular edema (DME) is a major cause of visual loss in patients with diabetes
mellitus. The standard treatment is with focal/grid laser therapy. Topical nepafenac was used
as an adjunct therapy for treatment of DME.
The aim of this study is to compare the difference of best corrected visual acuity (BCVA) and
central macular thickness (CMT) at 3 months post treatment between combination therapy of
laser and topical nepafenac and laser monotherapy in patients with DME.
Phase:
Phase 4
Details
Lead Sponsor:
Universiti Sains Malaysia University of Science Malaysia